• Publications
  • Influence
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
BACKGROUND The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS We randomlyExpand
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
BACKGROUND The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODSExpand
A controlled trial of renal denervation for resistant hypertension.
BACKGROUND Prior unblinded studies have suggested that catheter-based renal-artery denervation reduces blood pressure in patients with resistant hypertension. METHODS We designed a prospective,Expand
Rivaroxaban in patients with a recent acute coronary syndrome.
BACKGROUND Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-doseExpand
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
BACKGROUND The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based on key baselineExpand
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of patients with cardiovascular disease. However, recurrent ischemic event occurrence during dual antiplateletExpand
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes.
BACKGROUND In short-term randomized trials (duration, 1 to 2 years), bariatric surgery has been associated with improvement in type 2 diabetes mellitus. METHODS We assessed outcomes 3 years afterExpand
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.
CONTEXT Atherothrombosis is the leading cause of cardiovascular morbidity and mortality around the globe. To date, no single international database has characterized the atherosclerosis risk factorExpand
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
BACKGROUND We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS In this double‐blindExpand
...
1
2
3
4
5
...